Rivaroxaban Committee Review May Hinge On Concerns About Off-Label Use
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J’s oral anticoagulant Xarelto has solid, but not strong, data for limited surgery claims; bleeding is among the safety worries.